Peripheral blood stem cell autografts for the treatment of childhood cancer: a review of the Japanese experience. Japanese Cooperative Study Group of PBSCT (JCSG/PBSCT).
Harvesting peripheral blood stem cells (PBSC) for autografts (PBSCT) in children with active cancers is a safe and reliable procedure with a low incidence of serious morbidity. A significant correlation between the number of infused CFU-GM and the time to both granulocyte and platelet engraftment was found. Cells induced by G-CSF could speed the recovery of granulocyte or platelet counts after PBSCT. In terms of preserving engraftment potential, cryopreservation of PBSC by a simplified uncontrolled-rate method is at least as effective as the traditional controlled-rate freezing procedure with a programmed freezer. As the serum G-CSF level increases immediately following infusion of PBSC graft, therapy with G-CSF may have only a limited ability to further enhance hematopoietic recovery after PBSCT. Preliminary results of high-dose chemotherapy without TBI and PBSCT for the treatment of children with relapsed ALL are encouraging.
Takaue
Y
Y
Department of Pediatrics, University Hospital of Tokushima, Japan.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001793:Blood Preservation; D001804:Blood Transfusion, Autologous; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D015925:Cryopreservation; D000069585:Filgrastim; D006085:Graft Survival / Q000187:drug effects; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use; D006410:Hematopoiesis / Q000187:drug effects; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D007564:Japan / Q000453:epidemiology; D007937:Leukapheresis; D007938:Leukemia / Q000188:drug therapy / Q000628:therapy; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D016879:Salvage Therapy
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim